Phase III Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The Phase III main study is a randomized, controlled, multicenter, double-masked, parallel
trial to evaluate the efficacy and safety of 0.25% TP-03, for the treatment of Demodex
blepharitis in China. The PK sub-study is a single-arm, open-label trial to evaluate systemic
Lotilaner PK of 0.25% TP-03 in whole blood following topical ocular administration